C1: ‘We shall find.’

The C1 single-cell sequencer from Fluidigm revolutionised the field of life science research by enabling researchers to explore tumour heterogeneity to better understand, among other things, cancer pathologies and mechanisms — and how new treatment designs could stop them.

One of the methods scientists use to do this is called single-cell mRNA sequencing, and the introduction of this capability required a campaign that adequately captured the challenge and privilege of literally breaking boundaries. This was the spark behind the ‘We shall find’ campaign.